The research community's rapid acceptance of microarrays notwithstanding, technical challenges remain. Biochip developers continue to grapple with these issues while upgrading their offerings and ...
The phase 1/2 randomized trial compared results from the measles and rubella vaccine delivered by a microarray patch, a small sticking plaster-like device with an array of microscopic projections that ...
The Microarray Innovations in Leukemia study assessed the clinical utility of gene expression profiling as a single test to subtype leukemias into conventional categories of myeloid and lymphoid ...
Different applications have different requirements, so researchers need to carefully weigh their options when deciding whether to switch to a new platform. [© WavebreakmediaMicro – Fotolia.com] With ...
This expansion solidifies Panther’s Pittsburgh base as a hub for next-generation process and discrete manufacturing, anchored by the discoveries and discipline developed through its BioForge ...
Curious about how to detect and characterize tumor-derived biomarkers from liquid biopsy samples? Genomics-based methods now provide access to more molecular data than ever before, delivering cancer ...
Vaxxas holds an exclusive license from The University of Texas at Austin (UTA) to the SARS-CoV-2 spike subunit vaccine (HexaPro) for vaccination using a patch. HexaPro, a second-generation SARS-CoV-2 ...
Medical Device Network on MSN
Vaxxas gains Australia’s TGA licence to manufacture HD microarray patch
Vaxxas has received a manufacturing licence from Australia’s Therapeutic Goods Administration (TGA) for its high-density microarray patch (HD-MAP) for clinical studies at a biomedical facility in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback